Mackie Research analyst André Uddin reviewed the state of affairs for drug developer Bellus Health ... Read More
Negative top-line results from its Phase 2 clinical study are cause for a rating change on Bellus He... Read More
Mackie Research analyst André Uddin is holding steady with Bellus Health (Bellus Health Stock Quote... Read More
Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising... Read More
After the fourth quarter and year end results from Bellus Health (Bellus Health Stock Quote, Chart T... Read More
Bellus Health (Bellus Health Stock Quote, Chart TSX:BLU) is all cashed-up to start a Phase II trial ... Read More
Share
